Cargando…

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK

OBJECTIVE: To use a discrete choice experiment (DCE) to evaluate preferences for the actual treatment features and overall profiles of two injectable glucagon-like peptide-1 receptor agonists (dulaglutide and liraglutide) among patients with type 2 diabetes mellitus (T2DM) in the UK. METHODS: In-per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelhorn, Heather L, Poon, Jiat-Ling, Davies, Evan W, Paczkowski, Rosirene, Curtis, Sarah E, Boye, Kristina S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646588/ https://www.ncbi.nlm.nih.gov/pubmed/26635470 http://dx.doi.org/10.2147/PPA.S90842

Ejemplares similares

Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
por: Gelhorn, Heather L, et al.
Publicado: (2016)

Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Matza, Louis S., et al.
Publicado: (2018)

Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2017)

Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Matza, Louis S., et al.
Publicado: (2018)

Estimating meaningful change for The Impact of Weight on Self-Perception (IW-SP) questionnaire among people with type 2 diabetes
por: Gelhorn, Heather L., et al.
Publicado: (2023)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study
por: Boye, Kristina S., et al.
Publicado: (2022)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
por: Boye, Kristina S., et al.
Publicado: (2019)

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2021)

The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes
por: Gelhorn, Heather L, et al.
Publicado: (2023)

Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK
por: Hall, G C, et al.
Publicado: (2013)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment
por: Igarashi, Ataru, et al.
Publicado: (2020)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review
por: Kennedy-Martin, Tessa, et al.
Publicado: (2018)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective
por: Gelhorn, Heather, et al.
Publicado: (2021)

Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Boye, Kristina S., et al.
Publicado: (2020)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

Preference for pharmaceutical formulation and treatment process attributes
por: Stewart, Katie D, et al.
Publicado: (2016)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments
por: Boye, Kristina S., et al.
Publicado: (2021)

Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment
por: Ng-Mak, Daisy, et al.
Publicado: (2017)

The Benefits of Safely Achieving Near Normoglycemia from the Perspective of People with Type 2 Diabetes: A Quantitative Survey Study
por: Gelhorn, Heather L, et al.
Publicado: (2022)

Satisfaction, Preference and Injection Habits of Switching to 200 Units/ml Insulin Lispro Pen from 100 Units/ml: A Patient Survey in Germany
por: Chen, Jieling, et al.
Publicado: (2021)

Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices
por: Zhou, Anna Y., et al.
Publicado: (2018)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

2499. Perceptions of and Preferences for Oral or Long-Acting Injectable Antiretroviral Treatment Regimens in the United States and Canada
por: Garris, Cindy, et al.
Publicado: (2019)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study
por: Qin, Lei, et al.
Publicado: (2017)

Patient and physician preferences for attributes of biologic medications for severe asthma
por: Gelhorn, Heather L, et al.
Publicado: (2019)

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment
por: Brooks, Anne, et al.
Publicado: (2019)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Managing the multifaceted nature of type 2 diabetes using once‐weekly injectable GLP‐1 receptor agonist therapy
por: Bzowyckyj, Andrew
Publicado: (2020)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Patients’ Preferences for Connected Insulin Pens: A Discrete Choice Experiment Among Patients with Type 1 and Type 2 Diabetes
por: Seo, Jaein, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r16k4deckiftnfb0bu5nsmsdkv